Back to Trials
NCT07197957Recruiting

Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury

BayCare Health System

Start Date

3/11/2025

Completion Date

2/28/2027

Summary

To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).

Detailed Description

The primary objective of this study is to evaluate the clinical utility of Cystatin C in early detection of contrast-induced AKI. To evaluate the effect of patient characteristics in the Cystatin C based GFR estimation in comparison to Cr based estimation.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Subjects ages 18 years and above * Inpatients with CKD (Figure 1) * Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media. * Pre and post contrast available * All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study. Exclusion Criteria: * Preexisting dialysis * Patients under the age of 18 years * Pregnancy * Incarcerated individuals * Patients with impaired cognition and unable to follow consent procedures * Recent exposure to CM (within 2 days before/after procedure) * Cardiac shock * Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Acute Kidney Injury

Locations

Morton Plant Hospital

Clearwater, Florida 33756

United States

Morton Plant North Bay Hospital

New Port Richey, Florida 34652

United States

Mease Countryside Hospital

Safety Harbor, Florida 34695

United States

St. Anthony's Hospital

St. Petersburg, Florida 33705

United States